do not combine dpp-4 inhibitors with glp-1 receptor agonists guideline Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology Lesson: A Clinical Overview of
Description
The possibility of providing preventive regimen in multi system pathologies is a significant use of the GLP-1RA in improving disease outcomes and preventing morbidity

Methods A disproportionality analysis was conducted using post-marketing data from the FAERS repository (2018 Q1 to 2022 Q4)

Front Aging Neurosci (2016) 8:108

Anderson, MD, MAS, an assistant professor of medicine from the University of Pittsburgh, clinical trials of several GLP-1 receptor agonists like semaglutide (Wegovy/Ozempic, Novo Nordisk) for weight loss included exclusion criteria of chronic medical and psychiatric conditions. However, [FDA] labeling does not restrict these treatments in these populations, they wrote in JAMA Internal Medicine
Oct 2004;93(4):497-500

Availability of this generic alternative is significant as the brand was recently discontinued*
